Please assess the completion status of the following clinical trial:

Trial Title: Phase 1 Safety Study of Dimethyl Sulfoxide Cryopreserved Platelets

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, at least 18 years of age.~* Ability to comprehend the study procedures and signed informed consent.~* If pre-menopausal female, must have a negative serum pregnancy test, and, if of child bearing potential, must be using an acceptable method of contraception.~* Diagnosed with any the following: acute leukemia (ALL or AML), chronic leukemia (CML, CLL, CMML, or hairy cell leukemia), myelodysplasia, aplasia, hematopoietic or non-hematopoietic solid tumor, or therapy (chemotherapy or radiation) induced bone marrow aplasia or hypoplasia. Either autologous or allogeneic bone marrow transplant or peripheral or cord blood stem cell recipients may be enrolled.~* WHO grade 2 or greater bleeding.~Exclusion Criteria:~* Acute or chronic DIC as evidence by D-dimer greater than 8 μg/mL and fibrinogen less than 100 mg (0.1 g)/dL. Both criteria must be met. If data are in the medical record for fibrin degradation products (FDPs), then FDP must be \<=40 μg/mL (FDP \>40 μg/mL is indicative of DIC).~* PT or aPTT \> 1.3 times the upper limit of normal for the laboratory.~* History of major operative procedures that required general anesthesia in the past 2 weeks.~* History of any prior major unprovoked thrombotic events and/or known inherited disorder of coagulation or platelet function (by history) (not to include clots in catheters, etc).~* A history or diagnosis of immune thrombocytopenia, thrombotic thrombocytopenic purpura, or hemolytic uremic syndrome.~* Females who are breastfeeding.~* Veno-occlusive disease or possible veno-occlusive disease.~* Receiving active, inpatient treatment with anti-platelet drugs and/or full anticoagulation therapy. Note: a heparin flush may be given daily and before and after blood draws to patients with a central line to keep the line patent.~* Subject previously enrolled in this study and received a study transfusion.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1 with 0.5 units of CPP (Type: EXPERIMENTAL): A single 30 to 60 minute intravenous (IV) infusion of 0.5 unit of dimethyl sulfoxide (DMSO) cryopreserved platelets (CPP)
- Cohort 1 with 1 unit of LSP (Type: ACTIVE_COMPARATOR): A single 30 to 60 minute intravenous (IV) infusion of 1 unit of liquid stored platelets (LSP)
- Cohort 2 with 1 unit of CPP (Type: EXPERIMENTAL): A single 30 to 60 minute intravenous (IV) infusion of 1 unit of dimethyl sulfoxide (DMSO) cryopreserved platelets (CPP)
- Cohort 2 with 1 unit of LSP (Type: ACTIVE_COMPARATOR): A single 30 to 60 minute intravenous (IV) infusion of 1 unit of liquid stored platelets (LSP)
- Cohort 3 with 2 units of CPP (Type: EXPERIMENTAL): A single 30 to 60 minute intravenous (IV) infusion of 2 units of dimethyl sulfoxide (DMSO) cryopreserved platelets (CPP)
- Cohort 3 with 1 unit of LSP (Type: ACTIVE_COMPARATOR): A single 30 to 60 minute intravenous (IV) infusion of 1 unit of liquid stored platelets (LSP)
- Cohort 4 with 3 units of CPP (Type: EXPERIMENTAL): A single 30 to 60 minute intravenous (IV) infusion of 3 units of dimethyl sulfoxide (DMSO) cryopreserved platelets (CPP)
- Cohort 4 with 1 unit of LSP (Type: ACTIVE_COMPARATOR): A single 30 to 60 minute intravenous (IV) infusion of 1 unit of liquid stored platelets (LSP

Based on this trial design, predict the completion outcome and termination type (if applicable).